Despite all of this, capivasertib has shown immense promise for the treatment of breast cancer, with positive results also being achieved in patients with Cowden syndrome [343], who inherit a defective PTEN gene in the germline and carry an 85% cumulative risk of developing breast cancer in their lifetime [42]. This evidence concerns the gene PTEN and breast cancer.